Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Quantum Biopharma ( (TSE:QNTM) ) has provided an announcement.
On June 26, 2025, Quantum BioPharma announced that its licensee, Unbuzzd Wellness Inc., has launched a $5 million capital raise to support its growth and potential IPO. This initiative, leveraging MZ Digital and Dealmaker, aims to expand the reach of ‘unbuzzd’, a beverage that speeds up alcohol metabolism and reduces hangover effects, following successful clinical trials. The capital raise is expected to enhance Unbuzzd’s market presence and sales, while also benefiting Quantum BioPharma through royalties and strategic positioning.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. Through its subsidiary, Lucid Psycheceuticals Inc., it is advancing its lead compound, Lucid-MS, for multiple sclerosis. Quantum BioPharma also retains a stake in Unbuzzd Wellness Inc., which markets the beverage ‘unbuzzd’ designed to accelerate alcohol metabolism and reduce hangover symptoms.
Average Trading Volume: 9,180
Technical Sentiment Signal: Buy
Current Market Cap: C$95.95M
See more insights into QNTM stock on TipRanks’ Stock Analysis page.